NASDAQ$BCYC
Bicycle Therapeutics plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter financial results and recent business progress.
Bicycle Therapeutics reported its first quarter financial results, highlighting the initiation of the Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer and progress across its pipeline.
- Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting.
- Continued progress across research and development (R&D) pipeline, with numerous clinical data readouts and updates expected in 2H 2024.
- Mike Hannay, D.Sc., FRPharmS, promoted to Chief Product and Supply Chain Officer
- Cash and cash equivalents of $457.0 million as of March 31, 2024, expected to provide financial runway into 2026
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$19.5M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro